Nonetheless, the same group has provided orthogonal support for this notion by showing that CRISPR-mediated disruption of mutant TP53 in a range of human cancer cell lines has no effect on proliferation or survival in vitro or following transplantation into immunocompromised animals [46]. This evidence concerns the gene TP53 and cancer.